TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04459715
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo administrated as oral solution from Day 1 to 14, every 21-day cycle.
Study: NCT01855217
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0,9% NaCl
Study: NCT02831257
Drug: AZD2014
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03163914
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine infusion rate will adjust 30 ml/h (5µg/ ml )
Study: NCT03163914
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norepinephrine infusion rate will adjust 30 ml/h (5µg/ ml )
Study: NCT02343445
Drug: P-1037
Normalized name: P
Approvals — FDA: no, EMA: no, PMDA: no
Description: P-1037 is a novel ENaC inhibitor
Study: NCT02343445
Drug: Hypertonic Saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.2% saline solution
Study: NCT00890084
Drug: Telmisartan or Telmisartan + Hydrochlorothiazide (HCTZ)
Normalized name: hydrochlorothiazide / telmisartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 40mg or 80mg +/- HCTZ 12.5mg or 25mg
Study: NCT03184194
Drug: nivolumab-daratumumab with low-dose cyclophosphamide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: nivolumab-daratumumab with low-dose cyclophosphamide will be given until progression
Study: NCT03340220
Drug: XPF-008
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule filled with XEN1101
Study: NCT03340220
Drug: XPF-010
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule filled with XEN1101
Study: NCT03075891
Drug: Doxycycline 40 mg MR (30 mg Immediate Release & 10 mg Delayed Release beads) capsules
Normalized name: doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 Capsule once-daily for 12 weeks
Study: NCT04053140
Drug: Penicillin G_600mg/hr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzylpenicillin IV administered in continuous dosing schedule. Dosage to be determined by closed-loop algorithm. Initial loading dose, and limits set to 600mg/hr.
Study: NCT00295035
Drug: CELECOXIB
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00780793
Drug: DMARD maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMARD maintenance
Study: NCT00298922
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500 mg tablets orally thrice weekly for 24 weeks
Study: NCT00298922
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet orally thrice weekly for 24 weeks
Study: NCT00916461
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Minocycline + treatment as usual. 50 mg twice daily increasing to 200 mgs per day, increments of 50 mgs every 2 weeks.
Study: NCT00916461
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + treatment as usual.
Study: NCT00560612
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: same as paroxetine (active comparator)
Study: NCT04241458
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01856530
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo nasal spray
Study: NCT04247282
Drug: M7824
Normalized name: M7824
Approvals — FDA: no, EMA: no, PMDA: no
Description: M7824 (1200 mg) will be administered intravenously on day 1 and 15 to patients enrolled in arm 1-3 (all three arms).
Study: NCT03995108
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to mavorixafor capsules
Study: NCT00643409
Drug: azithromycin SR (Zithromax; compound: CP-62,993)
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin SR 2.0 g by mouth in the form of a slurry x 1 dose
Study: NCT01804790
Drug: mFolfirinox
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational arm: Neoadjuvant chemotherapy mFolfirinox, 4 cycles: oxaliplatin: 85 mg/m² in 2 hours at D1 irinotecan: 180 mg/m² in 90 min at D1 folinic acid: 400 mg/m² simultaneously in 2 hours at D1 during the irinotecan infusion 5-FU: 2400 mg/m² continuous infusion during 48 hours (1200 mg/m² at D1 and D2), every 14 days during 2 months (4 cycles), then CRT (50 Gy (2 Gy/session, 25 fractions) + capecitabine 800 mg/m² twice a day 5 days/7), then surgery with TME 6-8 weeks after chemoradiation, and 4 months of adjuvant CT depending on the center's choice.
Study: NCT01804790
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1600 mg/m² (800 mg/m² twice daily) for 5 weeks
Study: NCT01804790
Drug: mFolfox6 or capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oxaliplatine 85 mg/m² (day 1 of cycle; perfusion in 2h), folinic acid 400 mg/m² (day 1 of cycle perfusion in 2h), 5-FU (bolus 400 mg/m² in 10 min and 2400 mg/m² perfusion continuous 46h). Arm A - 12 cycles ; Arm B - 6 cycles OR Capecitabine 2500 mg/m²/day (Each cycle consists of 1250 mg/m² twice daily for D1-14 then pause therapeutic from D15-21). Arm A - 8 cycles; Arm B 4 cycles.
Study: NCT02726711
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 - 4.0 mg IV to be infused
Study: NCT01107808
Drug: Calcium and Vit D
Approvals — FDA: no, EMA: no, PMDA: no
Description: ergocalciferol (vitamin D2) treatment 50,000 IU orally, weekly for 8 weeks calcium carbonate orally 1200mg daily
Study: NCT01210430
Drug: Ascorbic Acid (Vitamin C)
Normalized name: Ascorbic acid (vitamin C), plain
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive 60mg/kg of Ascorbic Acid over 20 minutes followed by a maintenance infusion of 20mg/kg.
Study: NCT01210430
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive 60mg/kg of normal saline over 20 minutes followed by a maintenance infusion of 20mg/kg of normal saline.
Study: NCT00811902
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet, oral administration
Study: NCT01209065
Drug: GSK1349572
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1349572 is an integrase inhibitor being developed for the treatment of human immunodeficiency virus -1 infection by ViiV Healthcare. This drug is experimental and has not been approved by the Food and Drug Administration (FDA).
Study: NCT01817894
Drug: Eflornithine cream 11.5 w/w %
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split face intervention with application of Eflornithine cream 11.5 w/w % versus no treatment for six months
Study: NCT02779699
Drug: AL2846
Approvals — FDA: no, EMA: no, PMDA: no
Description: AL2846 p.o. qd
Study: NCT03083561
Drug: LY3337641
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT03083561
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT01870362
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01746420
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: sodium acetate buffer (0 mg rhPDGF-BB)
Study: NCT01817582
Drug: Soothe® Lubricant Eye Drops
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00006280
Drug: Tobramycin for Inhalation
Normalized name: tobramycin Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01486901
Drug: isophane human insulin
Normalized name: insulin isophane, human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of each formulation, administered subcutaneously (s.c., under the skin) on two separate dosing visits
Study: NCT02296190
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intranasal administration via 4 prefilled Aptar Pharma Unit-Dose Spray devices
Study: NCT00085202
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02280239
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: one-time dose of acetaminophen 650mg given via the enteral route (via the gut)
Study: NCT02280239
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one-time dose of placebo (identical capsule) given via the enteral route (via the gut)
Study: NCT03866083
Drug: Extracorporeal Cytokine hemadsorption therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemoperfusion will be carried out for one session within 12 hours for all randomized patient using the adsorption columns for Jianfan Biotechnology Co., Zhuhai, China). The hemoperfusion apparatus will be connected in front of the hemodialyzer in series.
Study: NCT01690091
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomized into 2 groups (A succession: MET-placebo, B succession: placebo-MET. After 3 months the treatment will be switched.
Study: NCT01862263
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo of vildagliptin
Study: NCT01399047
Drug: Liquid Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dosage will be individualized, contingent upon the subject's weight. Subjects will receive 50% of the target dose (300mg/m2/dose BID) during Week 0-Week 2, then increase to the full dose (600mg/m2/dose BID) in Week 3, continuing at this dose through Week 8. Additionally, due to the risk of gastrointestinal disturbance (hemorrhage, ulcer), children will also receive prophylactic Prilosec (omeprazole) for the duration of the study, during both the mycophenolate and placebo arms.
Study: NCT03131713
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 1000mg
Study: NCT02515565
Drug: cephalosporin with or without erythromycin
Normalized name: erythromycin Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second- or third-generation cephalosporin (cefuroxime, cefotaxime, or ceftriaxone) with or without erythromycin, given parenterally; parenteral therapy should continue until the patient has been afebrile for more than 24 hours and oxygen saturation exceeds 95 percent.
Study: NCT01283334
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: For phase I, dose escalation will be 2.5 mg, 5 mg, 7.5 mg or 10 mg given orally on a daily basis.
Study: NCT00373672
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: identical in appearance to active comparator
Study: NCT03233529
Drug: Placebo ointment (vehicle)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ointment (vehicle) BID for 15 days (double blind)
Study: NCT00476268
Drug: Beclometasone dipropionate 250 µg/unit dose pMDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 inhalations bid
Study: NCT04437368
Drug: GT005; Low Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1 of the study will test two doses of GT005: Low Dose and High Dose.
Study: NCT04437368
Drug: GT005; High Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1 of the study will test two doses of GT005: Low Dose and High Dose.
Study: NCT04437368
Drug: GT005; Low Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 2 of the study will test one dose: Low Dose.
Study: NCT03430479
Drug: Cohort A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation + Nivolumab + hormone therapy
Study: NCT04242433
Drug: Direct Acting Antivirals
Normalized name: DIRECT ACTING ANTIVIRALS
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects with viremic chronic hepatitis C will be given DAAs based on the MMPHCRF Treatment algorithm. Patients will be assessed for cirrhosis, prior treatment exposure, high risk groups like dialysis patients, HIV-HCV coinfection, etc. Accordingly treatment will be provided at any of the 25 peripheral centres or at the apex nodal treatment centre (PGIMER) of the MMPHCRF.~Baseline and post treatment RAS samples will be collected with consent.
Study: NCT04317430
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: lactose tablets
Study: NCT00177853
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will start celecoxib (200mg PO BID) beginning 3-5 days prior to chemoradiation at home and receive the drug until 30 days following the completion of chemoradiation.
Study: NCT00601172
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match IV casopitant
Study: NCT02383368
Drug: ASP4132
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT04158674
Drug: Cernevit
Normalized name: Cernevit
Approvals — FDA: no, EMA: no, PMDA: no
Description: mixture of 12 vitamins The dilution of the treatment is done in a 500ml bag of 5% Glucose The product is administered as a continuous infusion for 24 hours at an initial rate of 0.2 µg/kg/min
Study: NCT01154569
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500 mg single dose
Study: NCT02422966
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02219581
Drug: Standard multimodal pain management regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: The standard multimodal postoperative pain management regimen typically used for total knee arthroplasty consists of the following:~Preoperative:~* Decadron: 10 or 20mg IV x 1 2 doses, 8 hours apart (if randomized to study group)~Intraoperative:~* Ropivacaine: Given intraoperatively. Capsule, subcutaneous tissue/skin. Administered in standard fashion. (300mg)~* Toradol: 30mg q 6hr for 6 total doses. 1st dose given intraoperatively at incision. The dose is 15 mg for older patients or if creatinine clearance (CrCl) is low.~Postoperative~* Tylenol: 1000mg po q 8hr (scheduled)~* Oxycodone: 5mg or 10mg q 3-4hr prn pain, If intolerant to Oxycodone: second agent line is Hydrocodone or Oral Dilaudid~* IV Morphine (or Dilaudid): 1 or 2 mg q 2hr prn breakthrough pain~* Morphine patient-controlled analgesia (PCA): only for failure of the above~* Morphine Sulfate (MS) Contin: Use as backup prn pain
Study: NCT02219581
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in the placebo arm will receive two doses of saline intravenously. The first dose will be given preoperatively within 3 hours of surgery and the second dose will be administered 8 hours after the first dose in the inpatient setting.
Study: NCT02162719
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received oral placebo matched to ipatasertib, daily on Days 1-21 of each 28-day cycle.
Study: NCT01115920
Drug: MTP-131 (Bendavia™)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 4 hour intravenous infusion
Study: NCT00697086
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02936544
Drug: BAY987521
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code:Z09-054)
Study: NCT00920985
Drug: Oral contraceptive (equivalent to the active treatment tablets of Levlite), 21-day blister SH D00593A
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21-day regimen per cycle (1 tablet a day for 3 weeks followed by a 7-day tablet-free period) for 7 cycles and placebo patches matching the conditions of the treatment of Arm 1
Study: NCT02000700
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One matching placebo tablet orally administered at baseline phase.
Study: NCT02332447
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be isotonic sodium chloride which preparation in 1 ml vials will be centralized by the pharmaceutical department of Edouard Herriot Hospital to ensure its indistinguishability from naloxone A single dose of 1 ml of naloxone (i.e 0.4 mg) or placebo will be administered by the supervising nurse or physician, using direct intravenous injection with a 5 ml syringe through peripheral venous catheter of which all patients will be equipped throughout the video-EEG.~The evolution from a partial seizure to a GTCS being gradual, and the total duration of the seizure ranging from 2 to 3 minutes, the injection will be prepared during the course of the seizure. Given the assumptions about the role of endogenous opioids release in the spontaneous termination of seizures, naloxone will be administrated immediately after the end of the GTCS and not before. Specifically, treatment administration will be performed within the 2 minutes following the end of the GTCS.
Study: NCT01762839
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous placebo was administered via 2 dedicated, peripheral venous lines, 1 in each arm. The infusion lasted approximately 3 hours.
Study: NCT00614523
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.
Study: NCT01060202
Drug: No intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is an observational study. Patients receiving bortezomib injection intravenously (into a vein) 1.3 mg/m2 twice a week for 21 days will be observed.
Study: NCT01037595
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo 3 time orally for 8 weeks
Study: NCT02382640
Drug: Maalox Advance Regular Strength liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maalox Advance Regular Strength liquid containing Aluminum Hydroxide 200 mg, Magnesium Hydroxide 200 mg, and Simethicone 20 mg/5 mL or equivalent
Study: NCT02339350
Drug: high dose methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: HD-MTX IV 5,000 mg/m2 I.V. over 4hr on day 0, 14, 28, 42 of SER interim maintenance schedule
Study: NCT00869284
Drug: CEEP regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: cyclophosphamide 1200 mg/m² intravenously on day 1 (d1), epirubicin 100 mg/m² intravenously on d1, vindesine 3 mg/m² intravenously on d1 and prednisone 80 mg/m² orally or intravenously on d1-5, with two weeks intervals
Study: NCT04481230
Drug: 99mTc-NTP 15-5 at a diagnostic activity of 5 MBq/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 intravenous injection of 99mTc-NTP 15-5 at a diagnostic activity of 5 MBq/kg (D0)
Study: NCT04481230
Drug: 99mTc-NTP 15-5 at a diagnostic activity of 10 MBq/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 intravenous injection of 99mTc-NTP 15-5 at a diagnostic activity of 10 MBq/kg (D0)
Study: NCT04481230
Drug: 99mTc-NTP 15-5 at a diagnostic activity of 15 MBq/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 intravenous injection of 99mTc-NTP 15-5 at a diagnostic activity of 15 MBq/kg (D0)
Study: NCT04638881
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo. Bolus and infusion administered similarly under general anesthesia.
Study: NCT01989689
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02232308
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules to match active drug will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.
Study: NCT03794219
Drug: oral naproxen
Normalized name: naproxen Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg/day oral naproxen is administered for 10 days.
Study: NCT00712881
Drug: Liposomal doxorubicin hydrochloride
Normalized name: DOXORUBICIN HYDROCHLORIDE LIPOSOME
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal doxorubicin hydrochloride will be administered per dose and schedule specified in the arm description.
Study: NCT00712881
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be administered per dose and schedule specified in the arm description.
Study: NCT00712881
Drug: Free doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Free doxorubicin hydrochloride will be administered per dose and schedule specified in the arm description.
Study: NCT02261948
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment should be initiated with a loading dose of 6-12 mcg / kg infused over 10 minutes followed by a continuous infusion of 0.1 mcg / kg / min.
Study: NCT00526669
Drug: Lapatinib and Capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral lapatinib (1250mg) administered as a monotherapy run-in followed by its combination with capecitabine
Study: NCT02089230
Drug: MEK 162
Normalized name: Mitogen-activated protein kinase (MEK) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase I Starting Dose of MEK 162: 15 mg by mouth twice a day in a 28 day cycle.~Phase II Starting Dose of MEK 162: Maximum tolerated dose from Phase I.
Study: NCT03014895
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT02149758
Drug: Etoricoxib
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00091247
Drug: tetracycline hydrochloride
Normalized name: Tetracycline Hydrochloride
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04454398
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diluent
Study: NCT01382472
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40 mg per operative in PPCI, the 40 daily during hospital stay
Study: NCT01382472
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No statin acutely. Simvastatin 20 mg from day 2.
Study: NCT01452997
Drug: NSAI treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 5% gel
Study: NCT01452997
Drug: Steroid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid intervention with 0.05% w/w clobetasone butyrate.
Study: NCT05139667
Drug: Corticosteroid Topical
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical tacrolimus and corticosteroids